Physician profile
Nasser Hambaz
NPI 1174533129
$14,420.30
in general payments reported to CMS, 2019-2025
51 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,102 · 2020: $1,367 · 2021: $1,542 · 2022: $1,403 · 2023: $2,402 · 2024: $2,262 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,945 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,945.47 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,178.02 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,300.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,012.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $945.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $943.79 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $841.39 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $819.80 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $681.31 | 2019-2025 | |
| Corcept Therapeutics | $539.93 | 2019-2025 | Korlym |
| Abbvie INC. | $407.94 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.96 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $340.74 | 2019-2025 | |
| Exact Sciences Corporation | $307.60 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $236.33 | 2019-2021 | |
| Dexcom, INC. | $231.25 | 2024-2025 | Dexcom G6 Transmitter |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $212.25 | 2020-2025 | Xarelto, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $207.30 | 2019-2024 | Trintellix |
| Mannkind Corporation | $188.37 | 2024 | |
| Shield Therapeutics INC | $173.73 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.55 | 2021 | |
| Almatica Pharma LLC | $136.38 | 2022-2023 | Gralise |
| Otsuka America Pharmaceutical, INC. | $133.33 | 2021-2023 | Abilify Maintena, Rexulti |
| Merck Sharp & Dohme LLC | $131.89 | 2019-2023 | Verquvo, Belsomra |
| Esperion Therapeutics, INC. | $131.23 | 2020-2025 | Nexletol |
| Medtronic, INC. | $99.36 | 2021-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Paratek Pharmaceuticals, INC. | $68.63 | 2024-2025 | Nuzyra |
| Abbott Laboratories | $51.62 | 2023-2025 | Freestyle Libre 3 |
| Verona Pharma, INC. | $45.76 | 2025 | Ohtuvayre |
| Phadia US INC. | $45.76 | 2024-2025 | Immunocap |
| Optinose US, INC. | $43.35 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $43.21 | 2019 | |
| Allergan, INC. | $40.56 | 2020 | |
| Vanda Pharmaceuticals INC. | $40.44 | 2020 | |
| Nabriva Therapeutics, Plc | $30.57 | 2021 | |
| Eisai INC. | $28.68 | 2024 | |
| Biogen, INC. | $27.05 | 2025 | Skyclarys |
| Xeris Pharmaceuticals, INC. | $24.52 | 2024 | Recorlev |
| Endo USA, INC. | $22.65 | 2025 | Aveed, Xiaflex |
| Ironshore Pharmaceuticals INC. | $22.17 | 2024 | |
| Recordati_rare_diseases_inc. | $22.13 | 2025 | Isturisa |
| Nevro Corp. | $21.62 | 2023 | Senza |
| Idorsia Pharmaceuticals US INC | $19.22 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $18.80 | 2021 | |
| Bausch Health US, LLC | $18.31 | 2020 | |
| Lundbeck LLC | $17.52 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $16.37 | 2025 | Zoryve |
| Insulet Corporation | $15.30 | 2019 | |
| Scynexis, INC. | $13.82 | 2022 | |
| Amarin Pharma, INC. | $13.72 | 2020 | |
| Currax Pharmaceuticals LLC | $13.72 | 2024 | Contrave |
| Shire North American Group INC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasser Hambaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.